Transdisciplināra pieeja ķermeniskās izpratības izpētē
Loading...
Date
Authors
Advisor
Journal Title
Journal ISSN
Volume Title
Publisher
Latvijas Universitāte
Language
N/A
Abstract
CILVĒKA EPIDERMĀLĀ AUGŠANAS FAKTORA RECEPTORA 2
(HER2) LOMA KRŪTS VĒŽA ADJUVANTĀS ĶĪMIJTERAPIJAS
IZVĒLĒ
Anotācija
Darba mērķis ir izpētīt HER2 receptora lomu krūts vēža adjuvantās ķīmijterapijas
izvēlē.
Materiāls un metodes
Pētījumā tika iekļautas 192 pacientes, kurām bija morfoloģiski verificēta krūts
vēža diagnoze un IHC noteikts HER2. Pacientēm bija izdarīta radikāla operācija un
vismaz 4 adjuvantas ķīmijterapijas kursi.
Secinājumi
1. Pacientēm ar krūts vēzi bez HER2 receptora pārmērīgas ekspresijas
ķīmijterapija bez antraciklīniem uzlaboja dzīvildzi bez recidīva salīdzinot ar
antraciklīnus saturošu ķīmijterapiju (p=0,003). Krūts vēža pacientēm ar HER2
receptora pārmērīgu ekspresiju būtiska dzīvildzes bez recidīva atšķirība netika
novērota (p=0,7).
2. Pacientēm ar krūts vēzi bez HER2 receptora pārmērīgas ekspresijas var
rekomendēt adjuvantu ķīmijterapiju bez antraciklīniem, arī gadījumā, ja ir
atrastas metastāzes reģionālos limfmezglos.
3. Krūts vēža pacientēm ar HER2 receptora pārmērīgu ekspresiju ir saglabāta
jutība pret antraciklīniem.
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) AND RESPONSE OF BREAST CANCER TO ADJUVANT CHEMOTHERAPY Abstract Aim of the Study is to determine the predictive value of HER2 expression for the selection of adjuvant chemotherapy in breast cancer patients. Material and Methods 192 breast cancer patients with histopathologically confirmed breast cancer, who had undergone radical surgery and received at least 4 courses of adjuvant chemotherapy with or without anthracyclines were included in the study. HER2 expression was evaluated by IHC. Conclusions 1. CMF chemotherapy produced improved recurrence free survival in breast cancer patients without HER2 overexpression when compared with anthracycline based chemotherapy(p=0,003). No differences in recurrence free survival were observed in breast cancer patients with HER2 overexpression (p=0,7). 2. Adjuvant chemotherapy without anthracyclines could be recommended for breast cancer patients without HER2 overexpression. 3. Breast cancer patients with HER2 overexpression are sensitive to antracycline based chemotherapy.
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) AND RESPONSE OF BREAST CANCER TO ADJUVANT CHEMOTHERAPY Abstract Aim of the Study is to determine the predictive value of HER2 expression for the selection of adjuvant chemotherapy in breast cancer patients. Material and Methods 192 breast cancer patients with histopathologically confirmed breast cancer, who had undergone radical surgery and received at least 4 courses of adjuvant chemotherapy with or without anthracyclines were included in the study. HER2 expression was evaluated by IHC. Conclusions 1. CMF chemotherapy produced improved recurrence free survival in breast cancer patients without HER2 overexpression when compared with anthracycline based chemotherapy(p=0,003). No differences in recurrence free survival were observed in breast cancer patients with HER2 overexpression (p=0,7). 2. Adjuvant chemotherapy without anthracyclines could be recommended for breast cancer patients without HER2 overexpression. 3. Breast cancer patients with HER2 overexpression are sensitive to antracycline based chemotherapy.